SNNUF
Smith & Nephew plc
Price Chart
Latest Quote
$15.10
+0.00 (+0.00%)
Current Price
| Previous Close | $15.10 |
| Open | $14.50 |
| Day High | $14.50 |
| Day Low | $14.50 |
| Volume | 1,000 |
Stock Information
| Quarterly Dividend / Yield | $0.39 / 2.59% |
| Shares Outstanding | 847.25M |
| Quarterly Dividend Yield | 2.59% |
| Quarterly Dividend | $0.39 |
| Total Debt | $3.33B |
| Cash Equivalents | $557.00M |
| Revenue | $6.16B |
| Net Income | $625.00M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $12.79B |
| P/E Ratio | 20.97 |
| EPS (TTM) | $0.72 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $15.60B |
| Sales | $6.16B |
| Income | $625.00M |
| Book/sh | $6.23 |
| Cash/sh | $0.66 |
| Employees | 17K |
Financial Ratios
| Quick Ratio | 1.17 |
| Current Ratio | 2.57 |
| Debt/Eq | 62.90 |
| EPS Growth TTM | 67.70% |
Returns & Margins
| ROA | 5.27% |
| ROE | 11.84% |
| Gross Margin | 68.25% |
| Operating Margin | 13.99% |
| Profit Margin | 10.14% |
Ownership
| Insider Ownership | 0.23% |
| Institutional Ownership | 70.62% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 14.80 |
| PEG | 1.21 |
| P/S | 2.08 |
| P/B | 2.42 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $14.96 |
| SMA50 | $15.40 |
| SMA200 | $16.25 |
| RSI | 100.00 |
| ATR | 0.0643 |
| Shares Float | 839.65M |
| Volatility | 0.67 |
Performance History
| Week | +1.27% |
| Month | +1.00% |
| Quarter | -1.41% |
| 6 Months | +5.36% |
| YTD | -7.09% |
| Year | +1.46% |
| 3 Years | +9.60% |
| 5 Years | -21.30% |
| 10 Years | +18.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $15.10 | 0 |
| 2026-06-11 | $15.10 | 0 |
| 2026-06-10 | $15.10 | 0 |
| 2026-06-09 | $15.10 | 0 |
| 2026-06-08 | $15.10 | 46,800 |
| 2026-06-05 | $14.91 | 0 |
| 2026-06-04 | $14.91 | 0 |
| 2026-06-03 | $14.91 | 0 |
| 2026-06-02 | $14.91 | 0 |
| 2026-06-01 | $14.91 | 0 |
| 2026-05-29 | $14.91 | 0 |
| 2026-05-28 | $14.91 | 0 |
| 2026-05-27 | $14.91 | 0 |
| 2026-05-26 | $14.91 | 0 |
| 2026-05-22 | $14.91 | 0 |
| 2026-05-21 | $14.91 | 0 |
| 2026-05-20 | $14.91 | 0 |
| 2026-05-19 | $14.91 | 1,800 |
| 2026-05-18 | $14.95 | 0 |
About Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
đ° Latest News
Smith & Nephew and 4 More Stocks See Action From Activist Investors
Barrons.com âĸ 2026-06-05T23:02:00Z
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading
MT Newswires âĸ 2026-06-03T15:10:58ZBernstein Cuts PT on Smith & Nephew plc (SNN)
Insider Monkey âĸ 2026-05-26T12:08:46Z
Medical Device Stocks Are Ready to Bounce. Two Names to Buy Now.
Barrons.com âĸ 2026-05-13T18:52:00Z
VEEV Boosts MedTech Quality Management With Smith+Nephew Partnership
Zacks âĸ 2026-05-13T16:25:00Z
Tennessee's top export is not whiskey or country music, it's this
The Tennessean âĸ 2026-05-13T09:07:16Z
Smith & Nephew and Four More Stocks See Action From Activist Investors
Barrons.com âĸ 2026-05-08T22:47:00Z
FTSE 100 Live: Fresnillo and Rolls lead soaring stocks as US 'close to' Iran deal
Proactive âĸ 2026-05-06T06:15:00Z
SNN vs. BSX: Which Stock Is the Better Value Option?
Zacks âĸ 2026-05-05T15:40:02Z
Canaccord Cuts PT on Smith & Nephew (SNN) Ahead of Fiscal Q1 Results
Insider Monkey âĸ 2026-05-01T08:17:09Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,764,000,000 | $1,730,000,000 | $1,540,000,000 | $1,543,000,000 |
| Cost Of Revenue | $1,764,000,000 | $1,730,000,000 | $1,540,000,000 | $1,543,000,000 |
| Total Revenue | $5,810,000,000 | $5,549,000,000 | $5,215,000,000 | $5,212,000,000 |
| Operating Revenue | $5,810,000,000 | $5,549,000,000 | $5,215,000,000 | $5,212,000,000 |
| Expenses | ||||
| Interest Expense | $168,000,000 | $139,000,000 | $91,000,000 | $93,000,000 |
| Total Expenses | $4,950,000,000 | $4,929,000,000 | $4,581,000,000 | $4,530,000,000 |
| Net Non Operating Interest Income Expense | $-149,000,000 | $-105,000,000 | $-74,000,000 | $-91,000,000 |
| Total Other Finance Cost | $5,000,000 | - | $-3,000,000 | $4,000,000 |
| Interest Expense Non Operating | $168,000,000 | $139,000,000 | $91,000,000 | $93,000,000 |
| Operating Expense | $3,186,000,000 | $3,199,000,000 | $3,041,000,000 | $2,987,000,000 |
| Selling And Marketing Expense | $2,276,000,000 | $2,218,000,000 | $2,066,000,000 | $2,013,000,000 |
| General And Administrative Expense | $376,000,000 | $384,000,000 | $369,000,000 | $381,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $412,000,000 | $263,000,000 | $223,000,000 | $524,000,000 |
| Net Interest Income | $-149,000,000 | $-105,000,000 | $-74,000,000 | $-91,000,000 |
| Interest Income | $24,000,000 | $34,000,000 | $14,000,000 | $6,000,000 |
| Normalized Income | $579,943,775 | $439,844,828 | $397,604,255 | $536,518,771 |
| Net Income From Continuing And Discontinued Operation | $412,000,000 | $263,000,000 | $223,000,000 | $524,000,000 |
| Total Operating Income As Reported | $657,000,000 | $425,000,000 | $450,000,000 | $593,000,000 |
| Net Income Common Stockholders | $412,000,000 | $263,000,000 | $223,000,000 | $524,000,000 |
| Net Income | $412,000,000 | $263,000,000 | $223,000,000 | $524,000,000 |
| Net Income Including Noncontrolling Interests | $412,000,000 | $263,000,000 | $223,000,000 | $524,000,000 |
| Net Income Continuous Operations | $412,000,000 | $263,000,000 | $223,000,000 | $524,000,000 |
| Pretax Income | $498,000,000 | $290,000,000 | $235,000,000 | $586,000,000 |
| Special Income Charges | $-203,000,000 | $-195,000,000 | $-184,000,000 | $-14,000,000 |
| Interest Income Non Operating | $24,000,000 | $34,000,000 | $14,000,000 | $6,000,000 |
| Operating Income | $860,000,000 | $620,000,000 | $634,000,000 | $682,000,000 |
| Depreciation And Amortization In Income Statement | $245,000,000 | $258,000,000 | $261,000,000 | $237,000,000 |
| Depreciation Income Statement | $0 | $0 | $0 | $0 |
| Gross Profit | $4,046,000,000 | $3,819,000,000 | $3,675,000,000 | $3,669,000,000 |
| Per Share | ||||
| Diluted EPS | $0.47 | $0.30 | $0.26 | $0.60 |
| Basic EPS | $0.47 | $0.30 | $0.26 | $0.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $-35,056,225 | $-18,155,172 | $-9,395,745 | $-1,481,229 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,424,000,000 | $1,151,000,000 | $1,058,000,000 | $1,256,000,000 |
| Total Unusual Items | $-203,000,000 | $-195,000,000 | $-184,000,000 | $-14,000,000 |
| Total Unusual Items Excluding Goodwill | $-203,000,000 | $-195,000,000 | $-184,000,000 | $-14,000,000 |
| Reconciled Depreciation | $555,000,000 | $527,000,000 | $548,000,000 | $563,000,000 |
| EBITDA (Bullshit earnings) | $1,221,000,000 | $956,000,000 | $874,000,000 | $1,242,000,000 |
| EBIT | $666,000,000 | $429,000,000 | $326,000,000 | $679,000,000 |
| Diluted Average Shares | $876,595,745 | $873,754,153 | $874,509,804 | $878,177,014 |
| Basic Average Shares | $873,487,717 | $871,831,675 | $870,143,133 | $878,177,014 |
| Diluted NI Availto Com Stockholders | $412,000,000 | $263,000,000 | $223,000,000 | $524,000,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Tax Provision | $86,000,000 | $27,000,000 | $12,000,000 | $62,000,000 |
| Other Special Charges | $19,000,000 | $10,000,000 | $36,000,000 | $-70,000,000 |
| Restructuring And Mergern Acquisition | $184,000,000 | $185,000,000 | $148,000,000 | $84,000,000 |
| Amortization | $245,000,000 | $258,000,000 | $261,000,000 | $237,000,000 |
| Research And Development | $289,000,000 | $339,000,000 | $345,000,000 | $356,000,000 |
| Selling General And Administration | $2,652,000,000 | $2,602,000,000 | $2,435,000,000 | $2,394,000,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $1,207,000,000 | $1,115,000,000 | $992,000,000 | $1,181,000,000 |
| Total Assets | $10,354,000,000 | $9,987,000,000 | $9,966,000,000 | $10,920,000,000 |
| Total Non Current Assets | $5,933,000,000 | $5,957,000,000 | $6,110,000,000 | $6,496,000,000 |
| Other Non Current Assets | $24,000,000 | $18,000,000 | $12,000,000 | $15,000,000 |
| Non Current Deferred Taxes Assets | $350,000,000 | $274,000,000 | $177,000,000 | $201,000,000 |
| Investmentin Financial Assets | $9,000,000 | $8,000,000 | $12,000,000 | $10,000,000 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $9,000,000 | $8,000,000 | $12,000,000 | $10,000,000 |
| Goodwill And Other Intangible Assets | $4,058,000,000 | $4,102,000,000 | $4,267,000,000 | $4,387,000,000 |
| Other Intangible Assets | $1,032,000,000 | $1,110,000,000 | $1,236,000,000 | $1,398,000,000 |
| Current Assets | $4,421,000,000 | $4,030,000,000 | $3,856,000,000 | $4,424,000,000 |
| Hedging Assets Current | $47,000,000 | $27,000,000 | $47,000,000 | $39,000,000 |
| Prepaid Assets | $127,000,000 | $92,000,000 | $76,000,000 | $79,000,000 |
| Inventory | $2,387,000,000 | $2,395,000,000 | $2,205,000,000 | $1,844,000,000 |
| Other Receivables | $148,000,000 | $122,000,000 | $114,000,000 | $95,000,000 |
| Taxes Receivable | $34,000,000 | $33,000,000 | $37,000,000 | $106,000,000 |
| Accounts Receivable | $1,059,000,000 | $1,059,000,000 | $1,027,000,000 | $971,000,000 |
| Allowance For Doubtful Accounts Receivable | $-41,000,000 | $-45,000,000 | $-49,000,000 | $-57,000,000 |
| Gross Accounts Receivable | $1,100,000,000 | $1,104,000,000 | $1,076,000,000 | $1,028,000,000 |
| Cash Cash Equivalents And Short Term Investments | $619,000,000 | $302,000,000 | $350,000,000 | $1,290,000,000 |
| Cash And Cash Equivalents | $619,000,000 | $302,000,000 | $350,000,000 | $1,290,000,000 |
| Cash Equivalents | $200,000,000 | - | - | - |
| Cash Financial | $419,000,000 | $302,000,000 | $350,000,000 | $1,290,000,000 |
| Debt | ||||
| Net Debt | $2,506,000,000 | $2,583,000,000 | $2,326,000,000 | $1,852,000,000 |
| Total Debt | $3,321,000,000 | $3,084,000,000 | $2,872,000,000 | $3,339,000,000 |
| Long Term Debt And Capital Lease Obligation | $3,258,000,000 | $2,319,000,000 | $2,712,000,000 | $2,848,000,000 |
| Long Term Debt | $3,123,000,000 | $2,175,000,000 | $2,565,000,000 | $2,707,000,000 |
| Current Debt And Capital Lease Obligation | $63,000,000 | $765,000,000 | $160,000,000 | $491,000,000 |
| Current Debt | $2,000,000 | $710,000,000 | $111,000,000 | $435,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,089,000,000 | $4,770,000,000 | $4,707,000,000 | $5,352,000,000 |
| Total Non Current Liabilities Net Minority Interest | $3,558,000,000 | $2,499,000,000 | $2,992,000,000 | $3,221,000,000 |
| Derivative Product Liabilities | $16,000,000 | $0 | $13,000,000 | $0 |
| Tradeand Other Payables Non Current | $79,000,000 | $35,000,000 | $77,000,000 | $67,000,000 |
| Non Current Deferred Taxes Liabilities | $31,000,000 | $9,000,000 | $36,000,000 | $144,000,000 |
| Current Liabilities | $1,531,000,000 | $2,271,000,000 | $1,715,000,000 | $2,131,000,000 |
| Payables | $1,342,000,000 | $1,245,000,000 | $1,269,000,000 | $1,299,000,000 |
| Other Payable | $28,000,000 | $11,000,000 | $26,000,000 | $34,000,000 |
| Total Tax Payable | $232,000,000 | $218,000,000 | $214,000,000 | $222,000,000 |
| Accounts Payable | $1,082,000,000 | $1,016,000,000 | $1,029,000,000 | $1,043,000,000 |
| Equity | ||||
| Common Stock Equity | $5,265,000,000 | $5,217,000,000 | $5,259,000,000 | $5,568,000,000 |
| Total Equity Gross Minority Interest | $5,265,000,000 | $5,217,000,000 | $5,259,000,000 | $5,568,000,000 |
| Stockholders Equity | $5,265,000,000 | $5,217,000,000 | $5,259,000,000 | $5,568,000,000 |
| Retained Earnings | $5,018,000,000 | $4,906,000,000 | $5,026,000,000 | $5,225,000,000 |
| Long Term Equity Investment | $7,000,000 | $16,000,000 | $46,000,000 | $188,000,000 |
| Other | ||||
| Treasury Shares Number | $4,216,469 | $5,840,968 | $7,506,452 | $7,013,608 |
| Ordinary Shares Number | $873,487,717 | $871,831,675 | $870,143,133 | $878,177,014 |
| Share Issued | $877,704,186 | $877,672,643 | $877,649,585 | $885,190,622 |
| Tangible Book Value | $1,207,000,000 | $1,115,000,000 | $992,000,000 | $1,181,000,000 |
| Invested Capital | $8,390,000,000 | $8,102,000,000 | $7,935,000,000 | $8,710,000,000 |
| Working Capital | $2,890,000,000 | $1,759,000,000 | $2,141,000,000 | $2,293,000,000 |
| Capital Lease Obligations | $196,000,000 | $199,000,000 | $196,000,000 | $197,000,000 |
| Total Capitalization | $8,388,000,000 | $7,392,000,000 | $7,824,000,000 | $8,275,000,000 |
| Treasury Stock | $66,000,000 | $94,000,000 | $118,000,000 | $120,000,000 |
| Additional Paid In Capital | $635,000,000 | $635,000,000 | $635,000,000 | $632,000,000 |
| Capital Stock | $175,000,000 | $175,000,000 | $175,000,000 | $177,000,000 |
| Common Stock | $175,000,000 | $175,000,000 | $175,000,000 | $177,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $79,000,000 | $88,000,000 | $70,000,000 | $127,000,000 |
| Long Term Capital Lease Obligation | $135,000,000 | $144,000,000 | $147,000,000 | $141,000,000 |
| Long Term Provisions | $95,000,000 | $48,000,000 | $84,000,000 | $35,000,000 |
| Current Capital Lease Obligation | $61,000,000 | $55,000,000 | $49,000,000 | $56,000,000 |
| Current Provisions | $108,000,000 | $233,000,000 | $243,000,000 | $322,000,000 |
| Defined Pension Benefit | $63,000,000 | $69,000,000 | $141,000,000 | $182,000,000 |
| Investmentsin Associatesat Cost | $7,000,000 | $16,000,000 | $46,000,000 | $188,000,000 |
| Goodwill | $3,026,000,000 | $2,992,000,000 | $3,031,000,000 | $2,989,000,000 |
| Net PPE | $1,422,000,000 | $1,470,000,000 | $1,455,000,000 | $1,513,000,000 |
| Accumulated Depreciation | $-2,862,000,000 | $-2,772,000,000 | $-2,569,000,000 | $-2,454,000,000 |
| Gross PPE | $4,284,000,000 | $4,242,000,000 | $4,024,000,000 | $3,967,000,000 |
| Construction In Progress | $122,000,000 | $170,000,000 | $256,000,000 | $303,000,000 |
| Machinery Furniture Equipment | $3,373,000,000 | $3,277,000,000 | $3,042,000,000 | $2,976,000,000 |
| Properties | $789,000,000 | $795,000,000 | $726,000,000 | $688,000,000 |
| Finished Goods | $1,873,000,000 | $1,832,000,000 | $1,653,000,000 | $1,341,000,000 |
| Work In Process | $45,000,000 | $60,000,000 | $78,000,000 | $79,000,000 |
| Raw Materials | $469,000,000 | $503,000,000 | $474,000,000 | $424,000,000 |
| Other Investments | - | - | $12,000,000 | $10,000,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $606,000,000 | $181,000,000 | $110,000,000 | $469,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $987,000,000 | $608,000,000 | $468,000,000 | $877,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-381,000,000 | $-427,000,000 | $-358,000,000 | $-408,000,000 |
| Investing Cash Flow | $-569,000,000 | $-448,000,000 | $-472,000,000 | $-691,000,000 |
| Capital Expenditure Reported | $-381,000,000 | $-427,000,000 | $-358,000,000 | $-408,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $0 | $-158,000,000 | $0 |
| Issuance Of Capital Stock | $1,000,000 | $0 | $6,000,000 | $14,000,000 |
| Financing Cash Flow | $-86,000,000 | $-200,000,000 | $-926,000,000 | $-645,000,000 |
| Cash Dividends Paid | $-327,000,000 | $-327,000,000 | $-327,000,000 | $-329,000,000 |
| Common Stock Dividend Paid | $-327,000,000 | $-327,000,000 | $-327,000,000 | $-329,000,000 |
| Net Common Stock Issuance | $1,000,000 | $0 | $-152,000,000 | $14,000,000 |
| Common Stock Issuance | $1,000,000 | $0 | $6,000,000 | $14,000,000 |
| Net Other Financing Charges | - | $4,000,000 | $3,000,000 | $-4,000,000 |
| Dividends Received Cfi | - | $0 | $1,000,000 | $4,000,000 |
| Other | ||||
| Repayment Of Debt | $-705,000,000 | $-151,000,000 | $-881,000,000 | $-267,000,000 |
| Issuance Of Debt | $1,000,000,000 | $326,000,000 | $485,000,000 | $0 |
| End Cash Position | $617,000,000 | $300,000,000 | $344,000,000 | $1,285,000,000 |
| Beginning Cash Position | $300,000,000 | $344,000,000 | $1,285,000,000 | $1,751,000,000 |
| Effect Of Exchange Rate Changes | $-15,000,000 | $-4,000,000 | $-11,000,000 | $-7,000,000 |
| Changes In Cash | $332,000,000 | $-40,000,000 | $-930,000,000 | $-459,000,000 |
| Common Stock Payments | $0 | $0 | $-158,000,000 | $0 |
| Net Issuance Payments Of Debt | $295,000,000 | $175,000,000 | $-396,000,000 | $-267,000,000 |
| Net Short Term Debt Issuance | $-705,000,000 | $175,000,000 | $-407,000,000 | $-267,000,000 |
| Short Term Debt Payments | $-705,000,000 | $-151,000,000 | $-407,000,000 | $-267,000,000 |
| Short Term Debt Issuance | $0 | $326,000,000 | $0 | $0 |
| Net Long Term Debt Issuance | $1,000,000,000 | $0 | $11,000,000 | $0 |
| Long Term Debt Payments | $0 | $0 | $-474,000,000 | $0 |
| Long Term Debt Issuance | $1,000,000,000 | $0 | $485,000,000 | $0 |
| Net Investment Purchase And Sale | $-1,000,000 | $0 | $-2,000,000 | $-2,000,000 |
| Purchase Of Investment | $-1,000,000 | $0 | $-2,000,000 | $-2,000,000 |
| Net Business Purchase And Sale | $-187,000,000 | $-21,000,000 | $-112,000,000 | $-285,000,000 |
| Purchase Of Business | $-187,000,000 | $-21,000,000 | $-113,000,000 | $-285,000,000 |
| Taxes Refund Paid | $-140,000,000 | $-125,000,000 | $-47,000,000 | $-97,000,000 |
| Interest Received Cfo | $22,000,000 | $8,000,000 | $7,000,000 | $6,000,000 |
| Interest Paid Cfo | $-140,000,000 | $-104,000,000 | $-73,000,000 | $-80,000,000 |
| Change In Working Capital | $-107,000,000 | $-332,000,000 | $-535,000,000 | $-150,000,000 |
| Change In Payable | $16,000,000 | $-105,000,000 | $-25,000,000 | $82,000,000 |
| Change In Inventory | $-42,000,000 | $-178,000,000 | $-407,000,000 | $-151,000,000 |
| Change In Receivables | $-81,000,000 | $-49,000,000 | $-103,000,000 | $-81,000,000 |
| Other Non Cash Items | $121,000,000 | $98,000,000 | $66,000,000 | $74,000,000 |
| Stock Based Compensation | $40,000,000 | $39,000,000 | $40,000,000 | $41,000,000 |
| Depreciation And Amortization | $555,000,000 | $527,000,000 | $548,000,000 | $563,000,000 |
| Amortization Cash Flow | $230,000,000 | $221,000,000 | $229,000,000 | $237,000,000 |
| Depreciation | $325,000,000 | $306,000,000 | $319,000,000 | $326,000,000 |
| Pension And Employee Benefit Expense | $16,000,000 | $3,000,000 | $6,000,000 | $0 |
| Gain Loss On Sale Of PPE | $22,000,000 | $18,000,000 | $11,000,000 | $14,000,000 |
| Net Income From Continuing Operations | $498,000,000 | $290,000,000 | $235,000,000 | $586,000,000 |
| Gain Loss On Investment Securities | - | $4,000,000 | - | $1,000,000 |
| Gain Loss On Sale Of Business | - | $0 | $0 | $-75,000,000 |
| Sale Of Business | - | - | $1,000,000 | - |
Fetched: 2026-02-02